Gary D Miller1, Barbara J Nicklas, Adolfo Fernandez. 1. Department of Health and Exercise Science, Wake Forest University, Winston-Salem, North Carolina 27109-7868, USA. millergd@wfu.edu
Abstract
BACKGROUND: A number of proteins secreted from adipose tissue, known as adipokines, are involved in the inflammatory process. The expression and secretion of adipokines are altered with obesity, leading to a pro-inflammatory state, with an enhanced vascular immune response. Although weight loss reduces inflammation, the time course for these changes during massive weight loss after bariatric surgery is not well described. We examined the changes in the biomarkers of inflammation after laparoscopic Roux-en-Y gastric bypass (RYGB) in morbidly obese individuals in a university hospital. METHODS: The fasting levels of plasma inflammatory adipokines, including leptin, adiponectin, C-reactive protein (CRP), interleukin-6, tumor necrosis factor-α (TNF-α), and soluble receptor 1 for TNF-α were measured before surgery (baseline) and 3 weeks, 3 months, and 6 months after surgery in 15 morbidly obese patients who underwent Roux-en-Y gastric bypass without a major complication. RESULTS: The mean weight loss at 6 months was 25.7% ± 4.5% of the total body weight. The body mass index decreased from a mean of 55.1 ± 6.6 kg/m(2) to 40.5 ± 5.5 kg/m(2). The concentrations of leptin, CRP, and soluble receptor 1 for TNF-α decreased, and the adiponectin levels had increased from the baseline measures by 6 months postoperatively. The baseline and 6-month TNF-α and CRP levels correlated with each other. No other significant associations among the biomarkers were seen. CONCLUSION: RYGB reduced the pro-inflammatory biomarkers and increased the anti-inflammatory mediators of obesity, independent of the magnitude of weight loss. The lack of correlations between the changes in biomarkers and weight loss suggests that the driving force behind the changes in the inflammatory markers is multifactorial and needs further investigation to clarify the health changes that occur after RYGB.
BACKGROUND: A number of proteins secreted from adipose tissue, known as adipokines, are involved in the inflammatory process. The expression and secretion of adipokines are altered with obesity, leading to a pro-inflammatory state, with an enhanced vascular immune response. Although weight loss reduces inflammation, the time course for these changes during massive weight loss after bariatric surgery is not well described. We examined the changes in the biomarkers of inflammation after laparoscopic Roux-en-Y gastric bypass (RYGB) in morbidly obese individuals in a university hospital. METHODS: The fasting levels of plasma inflammatory adipokines, including leptin, adiponectin, C-reactive protein (CRP), interleukin-6, tumor necrosis factor-α (TNF-α), and soluble receptor 1 for TNF-α were measured before surgery (baseline) and 3 weeks, 3 months, and 6 months after surgery in 15 morbidly obesepatients who underwent Roux-en-Y gastric bypass without a major complication. RESULTS: The mean weight loss at 6 months was 25.7% ± 4.5% of the total body weight. The body mass index decreased from a mean of 55.1 ± 6.6 kg/m(2) to 40.5 ± 5.5 kg/m(2). The concentrations of leptin, CRP, and soluble receptor 1 for TNF-α decreased, and the adiponectin levels had increased from the baseline measures by 6 months postoperatively. The baseline and 6-month TNF-α and CRP levels correlated with each other. No other significant associations among the biomarkers were seen. CONCLUSION: RYGB reduced the pro-inflammatory biomarkers and increased the anti-inflammatory mediators of obesity, independent of the magnitude of weight loss. The lack of correlations between the changes in biomarkers and weight loss suggests that the driving force behind the changes in the inflammatory markers is multifactorial and needs further investigation to clarify the health changes that occur after RYGB.
Authors: V Mohamed-Ali; S Goodrick; A Rawesh; D R Katz; J M Miles; J S Yudkin; S Klein; S W Coppack Journal: J Clin Endocrinol Metab Date: 1997-12 Impact factor: 5.958
Authors: J Salas-Salvadó; M Bulló; P García-Lorda; R Figueredo; D Del Castillo; A Bonada; R Balanzà Journal: Int J Obes (Lond) Date: 2006-04-25 Impact factor: 5.095
Authors: M M Swarbrick; K L Stanhope; I T Austrheim-Smith; M D Van Loan; M R Ali; B M Wolfe; P J Havel Journal: Diabetologia Date: 2008-08-15 Impact factor: 10.122
Authors: Ying Liu; Simon Chewchuk; Charles Lavigne; Sophie Brûlé; Genevieve Pilon; Vanessa Houde; Aimin Xu; Andre Marette; Gary Sweeney Journal: Am J Physiol Endocrinol Metab Date: 2009-06-16 Impact factor: 4.310
Authors: N Vilarrasa; J Vendrell; R Sánchez-Santos; M Broch; A Megia; C Masdevall; N Gomez; J Soler; J Pujol; C Bettónica; H Aranda; J M Gómez Journal: Clin Endocrinol (Oxf) Date: 2007-07-02 Impact factor: 3.478
Authors: M Peters; S Jacobs; M Ehlers; P Vollmer; J Müllberg; E Wolf; G Brem; K H Meyer zum Büschenfelde; S Rose-John Journal: J Exp Med Date: 1996-04-01 Impact factor: 14.307
Authors: Derek K Hagman; Ilona Larson; Jessica N Kuzma; Gail Cromer; Karen Makar; Katya B Rubinow; Karen E Foster-Schubert; Brian van Yserloo; Peter S Billing; Robert W Landerholm; Matthew Crouthamel; David R Flum; David E Cummings; Mario Kratz Journal: Metabolism Date: 2017-02-02 Impact factor: 8.694
Authors: Katherine Samaras; Alexander Viardot; Natalia K Botelho; Alicia Jenkins; Reginald V Lord Journal: Diabetologia Date: 2013-09-13 Impact factor: 10.122